Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Reductions In NHI Prices Kyowa Hakko Kirin Reports Strong Pharma Sales, Revises Full Year Forecast

This article was originally published in PharmAsia News

Executive Summary

Despite National Health Insurance reimbursement price reductions, major drug maker Kyowa Hakko Kirin still saw a 52 percent increase in pharmaceutical sales and a 71 percent rise in operating income, which the company attributed to the synergy of the newly merged company during a third-quarter earnings call Jan 30
Advertisement

Related Content

Newly Merged Japanese Firm Files For First Drug Approval In China
Advertisement
UsernamePublicRestriction

Register

SC070846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel